🌅 Morning Brief — Thursday, October 1, 2026

Market Overview

It’s a new quarter kickoff with mixed signals: S&P 500 futures are edging higher (+0.2%) as markets digest a PCE print running hot (headline 3.7%, core 3.3%) — still well above the Fed’s 2% target, keeping rate-cut hopes on a slow burn. Accenture’s massive +21.7% earnings gap-up is the dominant story of the morning, sending a bullish ripple through the IT services, consulting, and AI-adjacent space, which explains the coordinated surge in CTSH, EPAM, INFY, GLOB, and EFOR. Meanwhile, TLT is hitting 6-month lows as the 10-year yield pushes toward 5.22%, a headwind for long-duration growth names heading into Q4.

Claude’s Call

UP — Accenture’s blowout earnings and the broad IT services sympathy rally have enough momentum to drag the S&P modestly higher on the day, but sticky PCE and JPMorgan’s warning about elevated equity positioning cap the upside; expect a grind higher (+0.3–0.6%) rather than a rip, with bonds continuing to bleed.

Top Movers

UTHR (+12.55%) — $541.89 → $630.64 (+16.4% upside) Thesis: This is a hard legal catalyst — a federal district court ruled Wednesday that Liquidia’s Yutrepia infringes on United Therapeutics’ inhaled treprostinil patents. That’s not a rumor or a conference headline; it’s a court decision that materially reduces near-term competitive risk to UTHR’s core PAH franchise. Layer on top the FDA’s acceptance of the ralinepag NDA (decision 2027) and this stock is repricing its IP moat in real time. Technically, UTHR broke above the key $534 fib 50% retracement and is now running toward the $567 fib 23.6% — that level will be the first test of sellers. Levels: Exit at $630.64 (fib 1.272 extension). Support at $534.49 (fib 50%) — a close below there would change the thesis.

VICR (+11.32%) — $321.66 → $440.75 (+37.0% upside) Thesis: Vicor dramatically raised Q3 revenue guidance, roughly doubling its expected sequential growth, driven by new patent-licensing royalties. The power components business is real, the AI data center angle is real (high-density power delivery), but here’s the honest caveat: Vicor has a documented history of royalty revenue being lumpy and non-recurring. The RSI at 77.2 flags this as overbought in the near term. The stock is up 107% from its 6-month low and approaching the $326 fib 23.6% resistance — expect a consolidation or pullback after the initial gap euphoria fades. If you’re already in: trail stops. If you’re not: wait for a dip toward $294 before adding. Levels: Exit at $440.75 (fib 1.272 extension). Support at $294.16 (fib 38.2%).

CTSH (+9.83%) — $63.08 → $71.75 (+13.7% upside) Thesis: Pure Accenture earnings sympathy, amplified by the fact that CTSH’s RSI was sitting at an extreme 9.16 — deeply oversold — before today’s move. That combination of a strong sector catalyst hitting a technically washed-out stock is one of the cleaner setups on this list. Cognizant has been executing on AI engineering tools with Cognition (live client deployments already), which gives this move at least some company-specific substance beyond pure sympathy. At $63, it’s still below its 6-month high of $64.64 — the breakout level is right there. If ACN’s results signal the IT services spending freeze is thawing, CTSH re-rates. Levels: Exit at $71.75 (fib 1.272 extension). Support at $58.47 (fib 23.6%) — the SMA50 at $58.52 confirms that level.

ZETA (+9.01%) — $31.57 → $37.60 (+19.1% upside) Thesis: Zeta Global is up 60.4% for Q3 on the back of its Athena AI marketing platform, and today’s move is partly riding the macro-data tailwind (PCE personal consumption +0.9% in August signals marketers will keep spending) and partly a continuation of that AI platform re-rating. RSI was at 12.59 — nearly as oversold as CTSH — so this is a deeply washed-out stock finding its footing. The stock is trading right near its 6-month high ($32.68), and the forward P/E of 26.9x is actually CHEAP vs. peer median of 36.2x for a 43.5% revenue grower. That’s a PEG under 0.7 — genuinely cheap if growth holds. Near-term resistance is the 6-month high at $32.68; a clean break above opens room to $37.60. Levels: Exit at $37.60 (fib 1.272 extension). Support at $28.17 (SMA50).

FORM (+9.59%) — $149.31 → $180.73 (+21.0% upside) Thesis: Deutsche Bank initiated with a Buy and a $200 price target, explicitly calling FormFactor Nvidia’s second-biggest supplier of chip-testing equipment. That’s a real analyst catalyst with a specific, differentiated thesis — not a sector-sympathy note. The semiconductor test equipment space benefits directly from AI chip complexity (more testing required per die). RSI is neutral at 50, the stock is near its 6-month high of $159.93, and the SMA50 at $114 is well below — meaning there’s been sustained institutional accumulation. This is a clean “buy the breakout toward the prior high” setup. Levels: Exit at $180.73 (fib 1.272 extension). Support at $141.88 (fib 23.6%).

ROG (+10.73%) — $152.99 → $183.84 (+20.2% upside) Thesis: Rogers Corp held an Investor Day outlining ~13% revenue CAGR through 2030, tied to AI data centers, vehicle electrification, and advanced materials. Management put specific targets on the table — that’s not vague storytelling. The stock ripped 17% in the morning session on the day, which tells you institutions were underweight. However, be honest: ROG is already up 73% over the past year and the prior research flagged valuation concerns. Today’s move takes it above prior resistance and into open air technically, but the risk of buying after a 73% run + 17% single-day pop is real. For fresh buyers, wait for a pullback to the $152 fib 23.6% level before entering. Levels: Exit at $183.84 (fib 1.272 extension). Support at $152.55 (fib 23.6%).

EPAM (+8.62%) — $117.71 → $154.84 (+31.5% upside) Thesis: Another Accenture sympathy trade, but EPAM has its own story — Engine Capital publicly pushed for a $750M buyback or a strategic sale in late August, and the RSI was at an extreme 8.30 (one of the most oversold readings on the entire list). EPAM has delivered 48.75% gains over 3 months even as the broader narrative has been uncertain. Today’s gap brings it back toward the $123 fib 23.6% level, which will be resistance. The buyback/strategic alternatives angle is a real underpin — at $117, this stock appears undervalued relative to the IT services peer group that is getting re-rated by ACN’s results. Levels: Exit at $154.84 (fib 1.272 extension). Support at $108.57 (SMA50).

INFY (+6.46%) — $11.45 → $15.15 (+32.3% upside) Thesis: Pure Accenture sympathy — Infosys is the large-cap Indian IT name that moves when ACN signals the outsourcing/IT services cycle is alive. RSI at 0.61 is literally the most oversold reading on this entire list. The stock is below its fib 61.8% support at $11.89, which means the longer-term trend is still down. But the ACN earnings catalyst + RSI at extreme low = violent snapback trade. The Chainlink/Infosys news is noise (blockchain partnership, not revenue driver). Play this as a short-duration mean-reversion, not a fundamental re-rating. Levels: Exit at $12.75 (fib 38.2% resistance, nearest overhead level). Support at $10.49 (6-month low).

Headlines to Watch

Accenture Surges +21.7% on Fiscal Q4 Beat Amid AI Disruption Worries — The most important read-through of the day: if the world’s largest IT consulting firm just crushed expectations citing AI as a growth driver (not a headwind), every IT services stock on your screen is worth a second look today — CTSH, EPAM, INFY, GLOB, and EFOR all have fundamental re-rating potential, not just sympathy pops.
Micron (MU) Posts Massive Beat but Stock Falls -1.55% — EPS of $74.34 on what appears to be a strong AI-driven HBM demand beat, yet the stock sells off — a classic “sell the news” after a +190% run from 6-month lows; the WSB 80% bull consensus at 1,277 mentions is exactly the crowded positioning that creates this dynamic.
10-Year Treasury Yield Hits 5.22%; PCE Headline 3.7%, Core 3.3% — Yields at this level are a live grenade for long-duration growth names and rate-sensitive sectors; TLT at 6-month lows confirms the bond market is NOT pricing in rate cuts — position sizing in high-multiple tech accordingly.
United Therapeutics Wins Patent Ruling vs. Liquidia — Court decisions blocking a generic/biosimilar competitor are the highest-quality catalyst in biotech; UTHR’s +12.5% move is justified and the ralinepag NDA adds a second act — this is not a one-day story.
JPMorgan Warns: Elevated Equity Positioning and Leverage Could Challenge Stocks in Q4 — The macro backdrop entering Q4 is not clean: hot inflation, high yields, crowded positioning, and leverage elevated — today’s rally may be a new-quarter window-dressing effect rather than a sustained breakout.
Rogers Corp Investor Day: 13% Revenue CAGR Through 2030 Targeting AI Data Centers and EVs — A company putting specific multi-year targets on AI infrastructure materials demand is a credible secular tailwind story — watch whether institutional investors use today’s gap as an entry or a fade opportunity.
Vicor Raises Q3 Revenue Guidance; Royalty-Driven Upside — High-density power conversion is genuinely tied to AI infrastructure buildout, but royalty revenue lumpiness is a documented risk — the 11% move is rational for the guidance raise, but don’t extrapolate the royalty line as recurring without confirmation.

Claude’s Top Picks

ZETA (+9.01% today, +5.98% week) — $31.57 → $37.60 (+19.1% upside) Valuation: Cheap — forward P/E of 26.9x vs. peer median 36.2x on 43.5% revenue growth implies a PEG of ~0.62, making this one of the few genuinely undervalued names in today’s mover list. Upside: Athena AI platform driving 60%+ Q3 gains, RSI recovering from extreme 12.59 oversold, and a macro PCE beat (consumer spending resilient) directly supports marketing technology budgets; next resistance is the 6-month high at $32.68, and a clean break targets $37.60. Risk: If the broader market sells off on hot PCE/yield concerns, high-growth software names get hit first regardless of valuation — SMA50 at $28.17 is your stop.

CTSH (+9.83% today, +10.35% week) — $63.08 → $71.75 (+13.7% upside) Valuation: No comp data provided, but relative to ACN and the IT services peer group, CTSH has historically traded at a discount — today’s re-rating off ACN’s beat is closing that gap. Upside: RSI was at 9.16 before today — extreme capitulation reversal + legitimate sector catalyst from ACN’s AI-driven beat is a high-conviction combination; right at the 6-month high breakout level at $64.64 sets up a squeeze if it clears cleanly. Risk: If ACN’s Q4 guidance disappoints when digested more carefully, the sympathy trade unwinds quickly — stop below $58.47 (fib 23.6% / SMA50 at $58.52).

UTHR (+12.55% today, +10.72% week) — $541.89 → $630.64 (+16.4% upside) Valuation: No comp data provided, but patent exclusivity on a core PAH drug with a pipeline NDA in review makes this a premium-multiple-justified biotech — the court ruling removes a near-term overhang that was likely weighing on valuation. Upside: Legal removal of the Liquidia competitive threat is a durable catalyst (not a one-day event), ralinepag NDA accepted with 2027 decision ahead, and the stock still has 16% room to the fib 1.272 extension at $630 — this has multi-week legs. Risk: Patent decisions can be appealed; if Liquidia announces an appeal or partial reversal, UTHR gives back the move fast — support at $519 (fib 61.8%).

FORM (+9.59% today, +13.75% week) — $149.31 → $180.73 (+21.0% upside) Valuation: No comp data provided, but a Deutsche Bank Buy initiation with a $200 target implies ~34% upside from current levels — and being explicitly named as Nvidia’s #2 chip testing supplier is a differentiated, durable positioning argument. Upside: AI chip complexity is accelerating demand for test equipment (more layers, more testing per wafer), RSI is neutral (not extended), and the SMA50 at $114 provides a deep backstop — there’s real institutional accumulation behind this name. Risk: Semiconductor capex cycles are notoriously cyclical; if NVDA or AMD signals any slowdown in advanced packaging, FORM is collateral damage — watch for any chip spending deceleration headlines.

EPAM (+8.62% today, +10.01% week) — $117.71 → $154.84 (+31.5% upside) Valuation: No comp data provided, but at $117 with Engine Capital publicly pushing for a $750M buyback or strategic sale, the activist angle creates a floor that pure fundamentals don’t fully capture. Upside: RSI at 8.30 was extreme oversold, ACN’s beat validates that enterprise IT spending is alive, and the activist buyback pressure provides a near-term corporate action catalyst that could narrow the valuation gap independently of the market. Risk: EPAM has geopolitical exposure (Ukraine-related delivery risk remains) and if the broader IT services rally fades post-ACN, the activist thesis needs more time to play out — stop at SMA50 $108.57.

Avoid

VICR — Already up 107% from 6-month lows, RSI at 77.2 signals overbought, the royalty revenue driving guidance is historically lumpy and non-recurring, and at $321 the stock is trading right at the fib 23.6% resistance level ($326.88) — chasing a royalty-driven guidance raise at these levels is a low-quality entry with significant mean-reversion risk back toward $267–294.

MNKD — Valued at 80.7x EV/EBITDA vs. a peer median of 14.9x (5x premium), forward P/E of 32x vs. peers at 15.5x — this is an extremely expensive small-cap biotech where the inhaled GLP-1 story (Rose Pharma deal) is very early stage with no clinical data yet; today’s 16.8% pop on no fresh catalyst looks like retail momentum, not institutional conviction, and volume ratio of only 1.0x confirms thin conviction behind the move.

AZUL — Brazilian airline up 26.4% on the week with no company-specific news beyond the United Airlines $100M investment from February — at $7.90 this looks like a delayed reaction trade on very thin volume (vol ratio 1.0x at near-zero), and airlines operating in Brazil face FX risk, fuel cost exposure, and macro sensitivity that makes a 14% single-day move with no fresh catalyst highly suspect; the stock is still 20% below its 6-month high.

WSB Sentiment Check

MU — WSB says: BULLISH (80% bullish, 1,277 mentions, 7,476 upvotes) Claude says: DISAGREE — The technicals show MU at $1,065 is still 12% below the 6-month high of $1,213, sitting right at the fib 23.6% support at $1,013 after a -1.55% post-earnings selloff despite a massive beat; 80% bullish sentiment at 1,277 mentions after a +190% run from the 6-month low is textbook crowded positioning — when bulls are this unanimous after the catalyst has already printed, the risk/reward tilts toward mean reversion toward the $890 fib 38.2% level, not a continuation squeeze.

NVDA — WSB says: MIXED (55% bullish, 87 mentions) Claude says: PARTIALLY AGREE — NVDA at $230 is approaching its 6-month high of $235.20, RSI and momentum are neutral (not extended), and the AI infrastructure thesis remains intact; 55% bullish is appropriately cautious given the stock needs to clear $235 resistance to confirm a new leg — the setup is constructive but not a screaming buy at current levels, with SMA50 at $217 as the real support that matters.

TSLA — WSB says: MIXED (55% bullish, 66 mentions) Claude says: DISAGREE — TSLA at $356 is trading below multiple fib retracement levels (23.6% at $410, 38.2% at $389), the current price is sitting right at the 61.8% support at $354 which is the last line before a deeper breakdown to the 6-month low at $298; the automaker sector had a brutal September, and with the stock 20% off its 6-month high, the “mixed” WSB sentiment understates the bearish chart structure — if $354 breaks, this sees $298 fast.

GOOG — WSB says: MIXED (55% bullish, 65 mentions) Claude says: PARTIALLY AGREE — GOOG at $345 is sitting between the fib 50% support at $346 and the 38.2% resistance at $358; the chart structure is technically neutral-to-constructive (above SMA50 at $341), and with AI investment cycle tailwinds and antitrust risk already partially priced in, the setup supports a modest long bias but not conviction — 55% bullish is about right.

TLT — WSB says: MIXED (55% bullish, 63 mentions) Claude says: DISAGREE — TLT is hitting its 6-month low at $77.08 right now, the 10-year yield is at 5.22% and rising, PCE is running at 3.7% headline with no Fed pivot in sight; 55% bullish on TLT is betting against a bond market that is aggressively pricing in “higher for longer” — the technical chart is a waterfall, and catching this knife on the basis of “it looks cheap” ignores the rate trajectory entirely; if 5.25% on the 10-year holds or breaks higher, TLT tests $73-74 next.

Earnings Scorecard

ACN — BEAT | Stock: +21.7% | Fiscal Q4 2026 The reaction is justified and arguably still insufficient — ACN brushed off every AI disruption bear thesis, delivered broad-based revenue growth across geographies and industries, and the +21.7% gap signals institutions were deeply underweight going in; this is a buy-the-dip-on-any-pullback for the IT services complex, and the read-through for CTSH, EPAM, INFY, and GLOB is unambiguously positive.

FDS — BEAT (Record Organic ASV, revenue +6.3% YoY) | Stock: +3.3% | Q4 2026 Muted reaction is fair — FactSet is a steady, high-quality compounder but 6.3% revenue growth doesn’t excite at a premium multiple; the market is correctly pricing this as “solid but not exciting” — hold if you own it, no reason to chase.

MU — BEAT (EPS $74.34, described as crushing views) | Stock: -1.55% | Fiscal Q4 2026 Classic “sell the news” on a stock that ran +190% from 6-month lows into the print; the -1.55% reaction is a mild disappointment response given the magnitude of the beat, suggesting guidance or forward commentary was less bullish than hoped — with analyst target at $1,533 and current price at $1,065, this is a buy-the-dip candidate if it holds the $1,013 fib 23.6% support, but wait for stabilization first.

NKE — REPORTED ($2.10 EPS) | Stock: +1.21% | Q1 FY2027 Muted +1.2% response suggests the beat was expected and guidance was uninspiring; with short interest elevated heading into the print, the lack of a squeeze means the structural concerns (China weakness, market share losses) remain unresolved — not a buy.

CAG — REPORTED (-$3.98 EPS) | Stock: -1.19% | Q1 FY2027 Negative EPS with guidance reaffirmed — the market’s -1.2% reaction is mild, which suggests the loss was non-cash/goodwill in nature; “pricing actions kick in” commentary is marginally positive but this is dead money until the turnaround shows in numbers.

AYI — REPORTED ($15.06 EPS, beat on earnings, missed revenue estimates) | Stock: -0.89% | Q4 FY2026 Revenue miss overrides earnings beat in the current environment — the market cares about top-line inflection for cyclical industrial names, not just cost-cutting beats; mild selloff is rational.

KMX — BEAT (Strong unit sales, CAF growth) | Stock: +0.78% | Q2 FY2027 CarMax beating on unit sales in a high-rate environment is genuinely encouraging for the used auto market; the +0.78% reaction feels slightly undercooked given the macro skepticism heading in — worth monitoring for delayed upside as the print is digested.

JEF — REPORTED ($3.64 EPS, record banking revenue, weaker trading) | Stock: +0.10% | Q3 FY2026 Flat reaction reflects the mixed composition — record IB revenue is great, but trading weakness offsets it; analyst target of $55.83 vs. current price suggests moderate upside but this is a show-me story until trading revenue recovers.

This brief is for informational purposes only and does not constitute financial advice. All targets and levels are analytical reference points, not guarantees of performance.